Can VOYXACT move beyond proteinuria? Otsuka’s two-year VISIONARY data may decide its FDA future
Otsuka will unveil two-year VISIONARY eGFR data for VOYXACT, a pivotal test of kidney preservation and its path to full FDA approval.
Pharma & Biotech
Pharma & Biotech
Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.